Cognito and Ochsner launch brain health collaboratory
Cognito Therapeutics and Ochsner Health have established a regional platform to evaluate Spectris, a non-invasive device that uses synchronized light and sound to stimulate gamma-frequency brain activity, alongside clinical infrastructure to assess its effectiveness in cognitive decline and Alzheimer's disease. The collaboratory will generate real-world data on treatment response, cost-effectiveness, and scalability across diverse populations.

